

ASX RELEASE

26 October 2021

### AMPLIA APPOINTS LEADING DRUG DEVELOPER AS ONCOLOGY CLINICAL ADVISOR

- Amplia appoints José Iglesias M.D. as Clinical Advisor providing access to extensive experience in the clinical development of new oncology drugs
- Dr Iglesias was responsible for the development of Abraxane® which is the cornerstone for the standard of care for pancreatic cancer, the first clinical indication for AMP945

**Melbourne, Australia:** Amplia Therapeutics Limited (ASX: ATX), (“Amplia” or the “Company”), a company developing new drugs for the treatment of cancer and fibrosis, is pleased to announce it has appointed pharmaceutical industry veteran, José L. Iglesias M.D., as Clinical Advisor.

Dr Iglesias has over 30 years’ experience in the pharmaceutical industry, primarily focused on the clinical development of new oncology drugs and has held senior executive leadership roles with many of the leading oncology pharmaceutical companies including Eli Lilly, AMGEN, Abraxis and Celgene. During this time, he has designed and overseen studies in all phases of clinical development (Phase 1 to Phase 4), including several oncology Phase 3 registration trials that involved a total of over 2,000 patients. Dr Iglesias was responsible for the Phase 3 development of Abraxane® in pancreatic cancer, lung cancer and metastatic breast cancer. As a result of this work, Abraxane became a new worldwide standard of care of the treatment of advanced pancreatic cancer.

“We are delighted that Dr Iglesias has agreed to be a Clinical Advisor to Amplia” said John Lambert, CEO and Managing Director of Amplia. “Dr Iglesias’ extensive experience in the clinical development of new oncology drugs will be invaluable as we run our Phase 2 clinical trial of AMP945 in pancreatic cancer patients starting early next year. José’s experience in leading the development of the current standard of care, to which we plan to add AMP945, will be particularly relevant and will greatly enhance our ability to both run the trial and interpret the emergent clinical data.”

Dr Iglesias commented: “I am very pleased to be working with Amplia on their exciting new approach to tackle pancreatic cancer. Pancreatic cancer continues to be such a devastating and poorly managed disease that new approaches to treatment, like the one being pursued by Amplia, are urgently required. I am really excited to join this great team of people at such an exciting stage of drug development.”

This ASX announcement was approved and authorised for release by the Board of Amplia Therapeutics.

- End -

#### For Further Information

Dr. John Lambert

CEO and Managing Director

[john@ampliatx.com](mailto:john@ampliatx.com)

[www.ampliatx.com](http://www.ampliatx.com)

**About Amplia Therapeutics Limited**

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).

**About Pancreatic Cancer**

Approximately 60,000 people in the US, and nearly 4,000 people in Australia, are diagnosed with pancreatic cancer each year. It is one of the most deadly cancers with a 5-year survival rate of only 5%-10%. The only potential cure available for pancreatic cancer is surgical excision. However, only 20% of patients are eligible for surgery with the remainder of patients having either localised, non-resectable (40%) or metastatic (40%) disease. The standard first-line therapy for these patients is chemotherapy with either gemcitabine/Abraxane® or FOLFIRINOX. Only 40%-50% of first-line patients are able to receive a second line therapy, and there is no standard treatment for second line pancreatic cancer patients.